Cargando…

Neuroprotective Effects of Cholinesterase Inhibitors: Current Scenario in Therapies for Alzheimer’s Disease and Future Perspectives

Alzheimer’s disease (AD) is a slowly progressive neurodegenerative disease conceptualized as a continuous process, ranging from mild cognitive impairment (MCI), to the mild, moderate, and severe clinical stages of AD dementia. AD is considered a complex multifactorial disease. Currently, the use of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moreira, Natália Chermont dos Santos, Lima, Jéssica Ellen Barbosa de Freitas, Marchiori, Marcelo Fiori, Carvalho, Ivone, Sakamoto-Hojo, Elza Tiemi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9108627/ https://www.ncbi.nlm.nih.gov/pubmed/35591949 http://dx.doi.org/10.3233/ADR-210061

Ejemplares similares

Novel Dual AChE and ROCK2 Inhibitor Induces Neurogenesis via PTEN/AKT Pathway in Alzheimer’s Disease Model
por: Moreira, Natália Chermont dos Santos, et al.
Publicado: (2022)

The absence of the autoimmune regulator gene (AIRE) impairs the three-dimensional structure of medullary thymic epithelial cell spheroids
por: Monteleone-Cassiano, Ana Carolina, et al.
Publicado: (2022)

Preferential induction of MLL(Mixed Lineage Leukemia) rearrangements in human lymphocyte cultures treated with etoposide
por: Brassesco, María Sol, et al.
Publicado: (2009)

Cholinesterase inhibitors as Alzheimer's therapeutics
por: Sharma, Kamlesh
Publicado: (2019)

Synthesis of Hantzsch Adducts as Cholinesterases and Calcium Flux inhibitors, Antioxidants and Neuroprotectives
por: Pachón Angona, Irene, et al.
Publicado: (2020)

Combining antioxidant astaxantin and cholinesterase inhibitor huperzine A boosts neuroprotection
por: Yang, Xin, et al.
Publicado: (2020)

Synergism of antihypertensives and cholinesterase inhibitors in Alzheimer's disease
por: Hu, Ziheng, et al.
Publicado: (2018)

Neuroactive Multifunctional Tacrine Congeners with Cholinesterase, Anti-Amyloid Aggregation and Neuroprotective Properties
por: Kozurkova, Maria, et al.
Publicado: (2011)

Exploring Mannosylpurines as Copper Chelators and Cholinesterase Inhibitors with Potential for Alzheimer’s Disease
por: Schino, Ignazio, et al.
Publicado: (2022)

Response to cholinesterase inhibitors affects lifespan in Alzheimer’s disease
por: Wattmo, Carina, et al.
Publicado: (2014)

Anti-cholinesterase and Neuroprotective Activities of Sweet and Bitter Apricot Kernels (Prunus armeniaca L.)
por: Vahedi-Mazdabadi, Yasaman, et al.
Publicado: (2020)

Alzheimer's disease and Type 2 diabetes mellitus: the cholinesterase connection?
por: Allam, Appa Rao, et al.
Publicado: (2006)

Memantine and Cholinesterase Inhibitors: Complementary Mechanisms in the Treatment of Alzheimer’s Disease
por: Parsons, Chris G., et al.
Publicado: (2013)

CHRNA7 Polymorphisms and Response to Cholinesterase Inhibitors in Alzheimer's Disease
por: Weng, Pei-Hsuan, et al.
Publicado: (2013)

Synthesis and Biological Evaluation of New Cholinesterase Inhibitors for Alzheimer’s Disease
por: Hussein, Weiam, et al.
Publicado: (2018)

Odor identification impairment and cholinesterase inhibitor treatment in Alzheimer's disease
por: Motter, Jeffrey N., et al.
Publicado: (2021)

Neuroprotective derivatives of tacrine that target NMDA receptor and acetyl cholinesterase – Design, synthesis and biological evaluation
por: Remya, Chandran, et al.
Publicado: (2021)

Cholinesterase Research
por: Korabecny, Jan, et al.
Publicado: (2021)

Cholinesterase inhibitory, anti-amyloidogenic and neuroprotective effect of the medicinal plant Grewia tiliaefolia – An in vitro and in silico study
por: Sheeja Malar, Dicson, et al.
Publicado: (2016)

Lymphocytes of Patients with Alzheimer’s Disease Display Different DNA Damage Repair Kinetics and Expression Profiles of DNA Repair and Stress Response Genes
por: Leandro, Giovana S., et al.
Publicado: (2013)

A critical review of cholinesterase inhibitors as a treatment modality in Alzheimer's disease
por: S. Schneider, Lon
Publicado: (2000)

Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease
por: Rountree, Susan D, et al.
Publicado: (2009)

Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic review
por: Farrimond, Lucy E, et al.
Publicado: (2012)

Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer’s disease cohort
por: Wattmo, Carina, et al.
Publicado: (2012)

Screening and analysis of acetyl-cholinesterase (AChE) inhibitors in the context of Alzheimer's disease
por: Khan, Mohd. Babu, et al.
Publicado: (2018)

Anti-Cholinesterase Combination Drug Therapy as a Potential Treatment for Alzheimer’s Disease
por: Amat-ur-Rasool, Hafsa, et al.
Publicado: (2021)

Effect of QT Prolongation in Patients Taking Cholinesterase Inhibitors (Donepezil) for Alzheimer’s Disease
por: Kuwahata, So, et al.
Publicado: (2021)

Development of substituted benzylidene derivatives as novel dual cholinesterase inhibitors for Alzheimer's treatment
por: Gupta, Shraddha Manish, et al.
Publicado: (2023)

Good rate of clinical response to cholinesterase inhibitors in mild and moderate Alzheimer's disease after three months of treatment: An open-label study
por: de Miranda, Luis Felipe José Ravic, et al.
Publicado: (2013)

Structure-Based Search for New Inhibitors of Cholinesterases
por: Bajda, Marek, et al.
Publicado: (2013)

Neuroprotective Efficacy of Europinidin in Streptozotocin-Induced Memory Impairment by Modulation of Oxidative Stress, Inflammatory Mediators, and Cholinesterase Activity in Rats
por: Ahmad, Aftab
Publicado: (2023)

Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer’s disease: A meta-analysis
por: Campbell, Noll, et al.
Publicado: (2008)

Synthesis of Brominated 2-Phenitidine Derivatives as Valuable Inhibitors of Cholinesterases for the Treatment of Alzheimer’s Disease
por: Abbasi, Muhammad Athar, et al.
Publicado: (2014)

Cholinesterase inhibitors in Alzheimer's disease and Lewy body spectrum disorders: the emerging pharmacogenetic story
por: Lam, Benjamin, et al.
Publicado: (2009)

Reassessment of the dementia diagnosis of Alzheimer's disease in patients enrolled on the cholinesterase inhibitors dispensation program
por: Piovesana, Magda Cristina Flaitt Sanches, et al.
Publicado: (2012)

Serum Concentrations of Cholinesterase Inhibitors in Patients With Alzheimer’s Dementia Are Frequently Below the Recommended Levels
por: Ortner, Marion, et al.
Publicado: (2020)

First-in-Class Isonipecotamide-Based Thrombin and Cholinesterase Dual Inhibitors with Potential for Alzheimer Disease
por: Purgatorio, Rosa, et al.
Publicado: (2021)

A method for the efficient evaluation of substrate-based cholinesterase imaging probes for Alzheimer’s disease
por: Darvesh, Sultan, et al.
Publicado: (2023)

Comparison of Cholinesterase Inhibitor Utilization Patterns and Associated Health Care Costs in Alzheimer's Disease
por: Mucha, Lisa, et al.
Publicado: (2008)

MLL leukemia-associated rearrangements in peripheral blood lymphocytes from healthy individuals
por: Brassesco, María Sol, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_0kbdeu3svoojlv86hdhav7lns4